## **DBCG - SKAGEN TRIAL 1**

## **PATHOLOGY REPORT**

DANISH BREAST CANCER COOPERATIVE GROUP

| Name – Patient ID   |                        |                                 | Hospital                                      |                |  |            |
|---|------------------------|---------------------------------|---|----------------|--|------------|
| Name Faulitie   |                        |                                 | rioopitai                                     |                |  |            |
| Day Month Year No.  |                        |                                 |   |                |  |            |
| Pathology report on patients included in the Skagen Trial 1   |                        |                                 |   |                |  |            |
| Surgical type   |                        | Size of invasive carcinoma (mm) |   |                |  |            |
| Axillary lymph node dissection ☐ No ☐ Yes   |                        |                                 | Resection margin from invasive carcinoma (mm) |                |  |            |
| Number of lymph nodes (LNs) removed in total  |                        |                                 | Resection margin from DCIS (mm)               |                |  |            |
| Number of LNs with macrometastas  |                        | Type of invasive carcinoma      | ☐ Ducta☐ Lobu☐ Othe                           | ılar           |  |            |
| Number of LNs with micrometastases  |                        |                                 | Malignancy grade                              |                |  | lot graded |
| Santing node highey right   | □ No<br>□ Yes          |                                 | ER status (%)                                 |                |  |            |
| Number of sentinel nodes  |                        |                                 | Ki67 (%)                                      |                |  |            |
|   |                        |                                 | HER2 status                                   | □ Norm □ Posit |  |            |
| Neoadjuvant or primary systemic therapy   |                        |                                 |   |                |  |            |
| Response of the primary tumour to neoadjuvant/primary systemic therapy  Grade 1 = No invasive cancer cells (presence of DCIS is a Grade 2 = More than 90% loss of cancer cells Grade 3 = Between 30 and 90% loss of cancer cells Grade 4 = Less than 30% loss of cancer cells |                        |                                 |   |                |  | wed)       |
| Response to neoadjuvant/primary systemic therapy in the axilla  |                        |                                 |   |                |  |            |
| Number of LNs with metastases and sign of response to therapy   |                        |                                 |   |                |  |            |
| Number of LNs without metastases and with sign of response to therapy   |                        |                                 |   |                |  |            |
|   |                        |                                 |   |                |  |            |
| Form filled in by:  |                        |                                 |   |                |  |            |
|   | Name:(CAPITAL LETTERS) |                                 |   |                |  |            |
|   | Sign.:                 |                                 |   |                |  |            |
| Date               ddmmyy   |                        |                                 |   |                |  |            |